Kornimate/medical-research-clean huggingface dataset:
graded motor imagery for patients within a year after stroke.

Conditions: Stroke

Summary: the aim of the study is to evaluate whether a graded rehabilitation approach including implicit and explicit motor imagery training and mirror therapy is more effective than other treatments commonly provided in a neuro-rehabilitation department.

graded motor imagery is a graded approach recently proposed for treating chronic pain patients. it included three subsequent steps: 1. implicit motor imagery training (imi), using a body part laterality discrimination task 2. explicit motor imagery training, using pictures and videos for improving patient's ability in imagining movements 3. mirror box therapy, using a 35x40 cm mirror, we are transferring this approach into stroke rehabilitation in order to improve patients' upper limb motor functions. all the patients, in both groups, will be training 2 hours a day, 5 days/week for 4 weeks. the first hour is standard treatment, the clinician in charge will decide treatment's priorities and the aim(s) of the treatment for each specific patient. the second hour will be focused on patient's upper limb function. the treatment group will be treated accordingly to the gmi protocol. the control group will receive a second hour of standard treatment, centred on the upper limb. standard treatments are decided by the interdisciplinary team and might include motor rehabilitation, bilateral arm training, virtual reality training or occupational therapy.

Eligibility criteria:
inclusion criteria: 1. ischemic or hemorrhagic stroke within a year from the event; 2. age of participant between 21 and 85 years old; 3. absence of apraxia or global aphasia; 4. mini-mental state examination score \>23. exclusion criteria: 1. presence of other neurological or orthopaedic disorders affecting upper extremity motor function, 2. neglect, 3. significant spasticity defined as a score ≥ 24 total points at tardieu rating scale (trs)

Keywords: stroke rehabilitation motor imagery upper extremity mirror therapy
evaluation of an antidepressant pharmacogenomic algorithm in an outpatient clinical setting

Conditions: Depression

Summary: this was a study of a genotyping tool that reported on how subjects responded to medications and could be used in a community psychiatry practice to improve medication choice for depression. after the dna test, an interpretive report was provided to the subjects' physicians. the hypothesis of this pilot study was that it was feasible to use this pharmacogenomic algorithm in a new setting to treat depressed subjects..

antidepressant medications are among the most widely prescribed medications. however, only 35% to 45% of depressed patients have a complete remission of their illness when initially treated with these medications. consequently, the mayo clinic psychiatric pharmacogenomic team developed a pharmacogenomic algorithm designed to improve the effectiveness and safety of antidepressant medications by providing guidance in medication selection and appropriate dosing. this algorithm has been incorporated into a new genotyping interpretative report. the pharmacogenomic algorithm is based on genotyping both copies of four informative genes. these four genes are: 1) the cytochrome (p450 2d6) gene; 2) the cytochrome (p450 2c19) gene; 3) the serotonin transporter gene (slc6a4); and 4) the serotonin 2a receptor gene (5htr2a). the trial took place at the franciscan skemp healthcare system in la crosse, wisconsin over the course of 12 months.

Eligibility criteria:
inclusion criteria: 1. patient is between the ages of 18 and 80. 2. major depressive disorder or depressive disorder not otherwise specified as ascertained by a physician or mental health professional licensed to diagnose. 3. patient is an outpatient and not in imminent need of inpatient hospitalization, or a discharging inpatient with scheduled follow-up with a behavioral health psychiatrist. 4. patient has been referred to see a psychiatrist for optimum medication management. 5. patient's hamilton depression rating score is \>14 6. ability to read, understand and sign an informed consent document exclusion criteria: 1. serious medical illness (as ascertained via the initial triage screening process) 2. patients with a diagnosis of bipolar i disorder 3. patients with a diagnosis of schizophrenia or schizoaffective disorder 4. patients who are legally unable to consent to enrollment in the study (i.e. patients with legal guardians)

Keywords: algorithm depression assurex genesight
study of blood lactate levels in patients treated with antipsychotics

Conditions: Movement Disorders; Lactic Acidosis

Summary: blood lactate levels in patients receiving typical or atypical antipsychotics have not been described in the literature. the goal of this study is to assess the dynamics of lactate levels in the blood from typical or atypical antipsychotics not confounded by prior antipsychotic treatments, the investigators conducted a prospective study of lactate levels in patients receiving antipsychotic medication. the investigators hypothesized that 6 months of treatment with haloperidol or olanzapine would result in a change in blood lactate levels and extrapyramidal side effects.

the aim of this study was to compare the blood lactate levels in patients receiving typical or atypical antipsychotics. subjects included sixty patients with psychotic disorder were assigned to treatment for 6 months with haloperidol (typical antipsychotic), n=30 or olanzapine (atypical antipsychotic), n=30. blood lactate levels, other metabolic parameters, and scores on the extrapyramidal symptom rating scale (esrs) were assessed.

Eligibility criteria:
inclusion criteria: * men aged 20 - 50 years * not taking any antipsychotic medication 1 month prior to the study * diagnosed psychotic disorder exclusion criteria: * female * tobacco use * diabetes mellitus * baseline lactate blood level over 2.0 mmol/l

Keywords: antipsychotics lactates side effects
registry study of chinese patients with marginal zone lymphoma (motive)

Conditions: Marginal Zone Lymphoma

Summary: this study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.


Eligibility criteria:
inclusion criteria: * be diagnosed as mzl * meet the treatment indications for mzl exclusion criteria: * any reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
a new model of acute febrile disease

Conditions: Immobilization, Tonic; Fasting; Endotoxemia; Metabolism

Summary: the investigators want to establish a new model of acute febrile disease by mimicking the conditions seen in hospitalized patients in regards to inflammation, immobilisation and fasting. in this new model of disease, healthy young adults will be given lipopolysaccharide (lps) to induce endotoxemia and inflammation/fever and then fast and bedrest for 36 hours. glucose, fat and protein metabolism will be investigated using clamp technique and tracer methodology together with intracellular signalling pathway activation in muscle and fat biopsies. this new model of disease will later be used in another study to investigate different protein supplement´s effect on muscle waste during acute febrile disease.

the investigators want to establish a new model of acute febrile disease by mimicking the conditions seen in hospitalized patients in regards to inflammation, immobilisation and fasting. in this new model of disease, healthy young adults will be given lipopolysaccharide (lps) to induce endotoxemia and inflammation on study day 1 and then fast and bedrest for 36 hours (study day 2). glucose, fat and protein metabolism will be investigated using clamp technique and tracer methodology together with intracellular signalling pathway activation in muscle and fat biopsies. this new model of disease will later be used in another study to investigate different protein supplement´s effect on muscle waste during acute febrile disease.

Eligibility criteria:
inclusion criteria: * male sex * 20 \< bmi \< 30 * 20 \< age \< 40 years * written consent prior to trial exclusion criteria: * participation in trials using ionized radiation a year prior to this trial. * comprehensive x-ray examinations in the study period. * in case of immobilization of an extremity, the extremity should be fully re- habilitated and this should be stated by a physician or physiotherapist. the test subject's word for this will be sufficient. * allergies to eggs or soy oil. * diseases: diabetes, epilepsy, ongoing infectious disease, immunodeficiency, heart disease, dysregulated hypertension.

Keywords: immobilization fasting endotoxemia lps metabolism model of disease
laser therapy in women with lichenoid disorders

Conditions: Lichen Sclerosus Et Atrophicus; Lichen Planus

Summary: primary aim of the trial is to compare improvement of lichen symptoms according to a composite vas scale (burning, itching and pain) between women with vulvovaginal laser therapy vs. sham laser therapy at three months.

background: lichenoid disorders (ld) include vls (vulvar lichen sclerosus) and lp (lichen planus). vls and lp are chronic skin diseases that usually affect the anogenital region. both can cause vulvar itching, burning and pain and can lead to urinary and sexual dysfunction. current treatment options are unsatisfactory. vulvovaginal laser therapy might be an effective treatment option. study aim: to study the effectiveness of non-ablative vulvovaginal laser therapy for women with lichenoid disorders. design: randomized double-blinded placebo- controlled clinical study study population: women diagnosed with ld will be recruited from a specialized university outpatient clinic. study groups: participants will be randomized (1:1). intervention group: laser therapy (2 treatments), plus ongoing therapy control group: sham laser therapy (2 treatments) plus ongoing therapy sample size total 40 patients primary study outcome: visual analogue scale (vas) composite score in regard to ld secondary study outcomes: quality of life (qol) (skindex questionnaire); treatment discomfort/ pain (vas); patient treatment satisfaction (questionnaire to ask for treatment satifsaction: zuf-8); subjective improvement (patient global impression of improvement- pgi-i), clinical ls score, histological appearance

Eligibility criteria:
inclusion criteria * women age \>18 years * diagnosed with ld (vls or lp histologically proven) * clinical ls score ≥ 4 based on the score of günthert et al. \[1\] * normal pap-smear within 24 months * negative clinical and microscopic evaluation of vaginal fluid * negative test for std (sexually transmitted diseases) pathogens (chlamydia, gonorrhea, genital mycoplasma and trichomonas) if symptomic including abdominal pain or abnormal vaginal fluid * good german language skills * written informed consent * preceding local corticoid therapy of at least 12 weeks according to the current guideline for ld exclusion criteria: * women with contraindications for the use of laser on the skin * pregnancy * presence of vulvar pathology (other than lichen) * any vulvar/ vaginal infection * immunocompromised women * swollen lymph nodes * genital malignant disease * allergy to topical anaesthesia * connective tissue disease * keloid formation * patients with a legal guardian * body mass index \> 35 kg/m² * history of transvaginal mesh implant (excluding sling or sacrocolpopexy mesh) * coagulopathy * patients using anticoagulants * patients with renal, hepatic or pulmonary-cardiovascular failure * patients who have undergone any kind of organ transplantation in the last three years.
evaluation of the effect of the presence of clowns on pain and anxiety seen during injections botulinum toxin in child

Conditions: Cerebral Palsy; Muscle Hypertonia

Summary: in children requiring botulinum toxin injections, improving supervisory procedures of injection sessions to reduce pain and improve the experience of this invasive procedure is needed. the intervention of medical clowns seems very interesting in this goal, but its effectiveness has not been proven within the botulinum toxin injections. the objective of the study is to evaluate in terms of profit the presence or absence of clowns during a session of botulinum toxins by determining their impact on pain and anxiety felt among children and their carers

in the literature, the presence of clowns allows a major reduction of pain and anxiety in children and their accompanying in various medical and hospital surgical settings. a previous study on a population of 60 children was conducted to assess the impact of the presence of clowns during the production of botulinum toxin injection in children but not confirming the benefit of their participation in carrying this medical procedure. the results of this study are opposed to current scientific data. their impact clown assessment criteria seem however insufficient to actually support the conclusion as to the ineffectiveness of distractibility clowns in this specific medical procedure iterative injection of botulinum toxin. the objective of the study is to evaluate the pain and anxiety before and after the botulinum toxin injection session in children and hetero-assessment of pain and anxiety by accompanying depending on the presence or not of clown. the second objectives are the evaluation of the course of the session by the injector doctor, the accompanying of the child and to evaluated the effect of distraction during the toxin of the clown or the usual distraction (music, movie...)

Eligibility criteria:
inclusion criteria: * children aged 1 to 18 years * children with a neurogenic spasticity (cerebral palsy, spastic paraplegia, head trauma ...) * children with muscular pains orthopedic disorders (popb, equino varus, ..) * botulinum toxin injection functional target, improvement in pain or amplitudes * first injection or repeated injections of toxins * no opposition formalized exclusion criteria: * children between 0 and 1 year * opposition formalized to the data use

Keywords: botulinum toxin anxiety reduction pain reduction medical clowns distraction
effect of repaglinide versus metformin treatment in non-obese patients with type-2-diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: aim: the united kingdom prospective diabetes study (ukpds) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference in glycemic control between treatments. non-obese patients with type-2-diabetes are usually treated with insulin-secretagogues or insulin when diet fails. since non-obese patients with type-2-diabetes also carry a high risk of cardiovascular events, the use of metformin for this sub-group of patients might be more beneficial. moreover, when insulin-treatment is initiated ongoing oral hypoglycaemic agents (oha) are often continued, but in non-obese patients with type-2 diabetes little evidence exist for choosing the optimal class of oha to be combined with insulin. the aim of the project is therefore to investigate the effect of metformin vs. an insulin-secretagogue (repaglinide) in combination with insulin on glycemic control and non-glycemic cardiovascular risk-factors in non-obese patients with type-2-diabetes, uncontrolled on diet alone. methodology: single-center, double-blind, double-dummy, randomized, parallel study involving 100 non-obese (bmi 27 kg/m2 or lower) patients with type-2-diabetes investigating the effect of treatment with metformin vs. repaglinide each in combination with biphasic insulin (insulin-aspart 30/70, biasp30) for a period of 12 months.

after four months run-in with repaglinide plus metformin combination-therapy, patients with hemoglobina1c ≥6.5% will be randomized (baseline=0 month) to repaglinide 2 mg thrice-daily or metformin 1g twice-daily, both in combination with biasp30 (30% insulin-aspart; 70% protaminated insulin-aspart) (6u once-daily, pre-dinner) for 12 months.

Eligibility criteria:
inclusion criteria: * non-obese patients (bmi \< 27 kg/m2) * type 2 diabetes * age 40 years or older * hba1c = 6.5% or higher at baseline. exclusion criteria: * no known contraindications for either of the study-drugs (known allergy to the study-drugs; heart-, liver- or kidney-failure) * pregnancy * other serious physical or mental illnesses with a life-shortening prognosis. * drug or alcohol abuse. * weight-loss of more than 5 kg during the last 6 month prior to enrollment.
what is the tympanic membrane healing time after insertion of a gelfoam pe tube?

Conditions: Eustachian Tube Dysfunction; Sudden Hearing Loss; Meniere Disease

Summary: pilot study done to evaluate the breakdown and and potential utility of a bioabsorbable ventilation ear tube made with gelatin.

institutional review board- park nicollet institute approval was granted 3/2011 for 15 patients to be enrolled in pilot study of use of a bioabsorbable ventilation ear (pe) tube. irb stated compliance with fda as defined in 21 cfr, part 56 and with regulations of dhhs. federal assurance number fwa00000914. prior to commencing this study, irb approval was obtained and each participating clinician completed the nih training for "protecting human research participants". 14 patients (15 ears) were enrolled in this study and were examined by 2 independent examiners at approximately 3, 6 and 12 week follow-ups. lumen patency and time to complete resorption were documented by each examiner. there were no adverse reactions. this pilot study suggests that there is utility for a bioabsorbable ear tube made from gelatin material, as the device was found to break down over the expected time frame and remained functional long enough to have clinical utility.

Eligibility criteria:
inclusion criteria: * meeting indications for placement of a short or intermediate-duration ventilation ear tube (pe tube) exclusion criteria: * none
the utility and cost-effectiveness analysis of 18f-fdg petin staging potential operable non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: we plan to conduct a prospective study: 1. to evaluate the accuracy of pet in staging patients with potentially operable non-small cell lung cancer; 2. to evaluate the percentage of futile thoracotomy after pet is introduced in the routine staging modalities for nsclc patient; 3. to establish a decision tree model based on choices between conventional imaging only and additional pet imaging to analyze their cost-effectiveness.

lung cancer has been a major health issue worldwide, including taiwan. according to the data published by the department of health, executive yuan, taiwan, 2004, lung cancer is already the leading cause of cancer-related death in taiwan. non-small cell lung cancer (nsclc) represents approximately 75-85% of all primary lung tumors. the strongest prognostic factor for survival is whether the tumor can be completely resected. surgical resection may be performed for those patients without distant or extended lymph node metastasis. because of the significant morbidity and mortality for surgical procedure of lung cancer, it is therefore very important to identify and exclude those patients who can't benefit from surgical treatment. conventional staging, using chest/brain x-ray computed tomography, abdominal echography and radionuclide bone scintigraphy, leads to futile thoracotomies in up to 50% of patients. since early 1990s, when 18f-fdg pet has emerged as a promising diagnostic imaging tool in nuclear medicine, a large number of studies have been reported without exception that pet is a better staging tool than ct for patients with nsclc. however, due to the prohibitive cost, pet is not routinely used for the staging of nsclc in taiwan. the extra cost accruing from the introduction of this new technology has been the major concerns from the clinical physicians and health policy makers. a number of economic evaluation studies overseas have shown that pet is cost-effective in nsclc when added to conventional work-up. however, due to that the sensitivity and specificity of 18f-fdg pet in staging nsclc, the cost structure of medical expense, the severity of disease for nsclc patients when they first present in the hospital, may be different between different countries. to the best of our knowledge, there has been no report that provides a practical guide to introduce pet in staging nsclc. a cost-effectiveness economic evaluation in taiwan is thus in demand. patient eligibility: inclusion criteria: patients with early nsclc (stage i \& ii) exclusion criteria: (1) patients who are pregnant (2) patients under 18 years old (3) patients who refuse surgical intervention (4) patients who have other known malignancy

Eligibility criteria:
inclusion criteria: * patients with non-small-cell lung cancer exclusion criteria: * patients who are pregnant * patients who are under 18 years old * patients who do not undergone surgery * patients who have other known malignancy

Keywords: nsclc staging 18f-fdg pet decision tree model cost-effectiveness
evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/ standard treatment in patients with suspected and mild novel coronavirus pneumonia (covid-19)

Conditions: Novel Coronavirus Pneumonia; 2019-nCoV

Summary: compare the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/ standard treatment in patients with suspected and mild, or common novel coronavirus pneumonia (covid-19). random, open, group sequential design.


Eligibility criteria:
inclusion criteria: * aged between 18 and 80 years (including 18and 80years, male or female). * one of them: 1. laboratory (rt-pcr) and clinical symptoms confirmed case of novel coronavirus pneumonia (covid-19). 2. patients diagnosed clinically as suspected cases. * ability to communicate well with researchers and sign the informed consent form (icf) voluntarily. exclusion criteria: * alt≥5 times of uln, level of total bilirubin≥3 times of uln, or cr≥1.5 times of uln. * patients with serious severe liver disease. * excluded who diagnosed as pneumonia patients with novel coronavirus infection of severe type and critical type. 【diagnostic criteria reference the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 5) "】. * patients with previous history of severe gastrointestinal diseases such as gastric ulcers and bleeding. * patients with lactose intolerance. * patients who are allergic to the components of this medicine (major components: bromhexine hydrochloride; excipient: starch, lactose, magnesium stearate). * positive serum pregnancy test result for women with childbearing potential at screening or lactating women. * other circumstances that the researcher considers inappropriate to participate in this study.